Experimental pill sends a THIRD of leukemia patients into complete remission in early trial
An experimental leukemia pill has shown promise in early clinical trials – sending a third of patients with aggressive disease into complete remission. The drug – revumenib – has also been credited with putting half of patients with acute myeloid leukemia (AML) into partial remission during phase one clinical trials. Dr Scott Armstrong, a blood … Read more